Research Article

Chelidonine Induces Caspase-Dependent and Caspase-Independent Cell Death through G₂/M Arrest in the T98G Human Glioblastoma Cell Line

Yeon-Kyeong Lee,¹ Ki Won Lee,¹ Minju Kim,¹ Yerin Lee,¹ Jiyun Yoo,^{1,2}
Cheol Hwangbo,² Ki Hun Park,¹ and Kwang Dong Kim ^{1,2,3}

¹Division of Applied Life Science (BK21Plus), Gyeongsang National University, Jinju 660-701, Republic of Korea

²Division of Life Science, Gyeongsang National University, Jinju 660-701, Republic of Korea

³PMBBRC, Gyeongsang National University, Jinju 660-701, Republic of Korea

Correspondence should be addressed to Kwang Dong Kim; kdkim88@gnu.ac.kr

Received 26 February 2019; Accepted 7 May 2019; Published 26 May 2019

Academic Editor: Luciana Dini

Copyright © 2019 Yeon-Kyeong Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chelidonium majus L. (family Papaveraceae), commonly known as greater celandine or tetterwort, has been reported to have antibacterial and anticancer effects and chelidonine is known as a functional metabolite extracted from *C. majus*. In this study, we observed the cytotoxicity of the alkaloid, chelidonine, and investigated its functional mechanism in T98G glioblastoma cell line. Chelidonine induced apoptosis in a dose-dependent manner, which was accompanied by decreased antiapoptotic protein Mcl-1. Caspase-3 and -9 were activated by treatment with chelidonine, but chelidonine-mediated apoptosis was only partially inhibited by a pan-caspase inhibitor. Chelidonine also induced the translocation of AIF into the nucleus; therefore, it is likely that chelidonine induces T98G cell death through both caspase-dependent and caspase-independent apoptosis pathways. Chelidonine also induced G₂/M arrest by inducing multipolar spindle assembly, which might also lead to cell death through inhibiting mitosis. Active CDK1, one of factors contributing to the prolongation of G₂/M phase, induced Mcl-1 degradation increasing mitochondrial instability, which is also an inducer of apoptosis in chelidonine-treated T98G cells. Taken together, these findings indicate that chelidonine induces apoptosis through G₂/M arrest and Mcl-1 degradation, implying that it may represent a compound for anticancer chemotherapy.

1. Introduction

Glioblastoma is the most aggressive primary brain tumor and is classified as a grade IV astrocytoma in the central nervous system [1]. Although remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy, the treatment of glioblastoma remains extremely difficult and can extend the lives of patients by only a few months [2]. According to previous reports, the survival rate of patients is only 3% - 5%, and death usually follows after a mean period of 12-15 months [3]. The highly invasive nature of glioma is the result of the ability of the cancer cells to extensively proliferate and infiltrate between normal brain cells, which makes them elusive targets for effective surgical management. In addition, several mechanisms responsible

for programmed cell death induction do not function, and molecular chaperones promoting cell survival are overexpressed in glioblastoma cells [4]. Therefore, the study of the signaling pathway inducing programmed cell death may be useful to identify the means of control that could provide novel cancer therapies for glioblastoma. Furthermore, alongside technological advances, scientific approaches based on traditional Chinese medical knowledge have provided a new direction for research into the treatment of cancers.

Chelidonium majus L. (family Papaveraceae) is widely used in traditional Chinese medicine. *C. majus* contains isoquinoline alkaloids (such as sanguinarine, chelidonine, chelerythrine, berberine, protopine, and coptisine), flavonoids, and phenolic acids as major compounds [5]. Crude extracts of this plant and purified compounds have been shown to

have a wide range of biological activities [6], including anti-inflammatory [7], antimicrobial [8], immunomodulatory [9], anticancer [10], choleric [11], hepatoprotective [12], and analgesic activities. Chelidone is a major alkaloid compound of *C. majus* extracts, which exhibits anticancer and antiviral properties [5].

In this study, we investigated the mechanism of chelidone-mediated cytotoxicity in the T98G human glioblastoma cell and conclude that chelidone could be developed as an anticancer drug for use against aggressive glioblastoma.

2. Materials and Methods

2.1. Cell Culture. The human glioblastoma cell line, T98G, the breast cancer cell lines, MCF7 and MDA-MB-231, human embryonic kidney cell line, HEK293, human endothelial cell line, HUVEC, and human skin fibroblast cell line, CCD-25Sk, were purchased from the American Type Culture Collection (ATCC) (VA, USA). The lung cancer line A549 was purchased from the Korean Cell Line Bank (Seoul, Korea). Cells were grown as a monolayer culture in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, MO, USA) or RPMI 1640 (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich) and 1% (v/v) penicillin/streptomycin (Lonza, Basel, Switzerland) solution at 37°C in an incubator containing 5% CO₂.

2.2. Reagents and Antibodies. Chelidone purchased from Sigma-Aldrich was used in this study. To inhibit apoptosis, the pan-caspase inhibitor Z-VAD-FMK (Enzo Life Sciences, Farmingdale, NY, USA) was used and dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was used as a vehicle. For western blot analysis, the following antibodies were used: anticaspase-3, caspase-9, poly (ADP-ribose) polymerase (PARP), Mcl-1, BAK, p-CDK1(Thr161), aurora A and p-PLK1 from Cell Signaling Technology (Beverly, MA, USA); anticyclin B1, CDK1, p-CDK1(Tyr15), and PLK1 from Santa Cruz Biotechnology (CA, USA); anti-BAX from BD Biosciences; anti-p-Ser/Thr-MPM-2 from Millipore; and anti- α -tubulin from Sigma-Aldrich. Anti-mouse IgG peroxidase conjugate and anti-rabbit IgG peroxidase conjugate from Sigma-Aldrich were used as secondary antibodies. For immunofluorescence assay, the following primary antibodies were used: anti-AIF from Santa Cruz, anti- α -tubulin from Sigma-Aldrich, and antipericentrin from abcam (Cambridge, MA, USA), and anti-mouse-FITC and anti-mouse-TRITC antibody were purchased from Sigma-Aldrich. To stain nucleus, we used DAPI from Sigma-Aldrich.

2.3. Cell Viability Assay. Cell lines were treated with 1.0 μ M chelidone for 24 h in 96-well plates and 20 μ l/well of CellTiter 96[®] Aqueous One Solution Reagent (MTS; Promega Corporation, WI, USA) was added. After 1.5 h at 37°C in a 5% CO₂-incubator, absorbance at 490 nm was measured using a Bio-Rad Model 680 microplate reader (Bio-Rad Laboratories).

2.4. Flow Cytometry. For cell cycle analysis, cells were harvested and fixed in ice-cold 70% ethanol (Merck, Darmstadt,

Germany) overnight at -20°C. The cells were centrifuged to remove the ethanol, washed with phosphate-buffered saline (PBS), suspended in 100 μ g/ml RNase (iNtRON Biotechnology, Seongnam, Korea) in PBS, and incubate for 2 h at 37°C, prior to addition of 10 μ g/ml propidium iodide (PI; Sigma-Aldrich). For the analysis of mitochondrial potential, cells were stained with 250 nM Mitotracker CMXRos (Invitrogen, CA, USA) for 30min at 37°C, then fluorescence was measured with a FACSVerse[™] flow cytometer (BD Bioscience, NJ, USA) and analyzed with FlowJo V10 software (FlowJo, OR, USA).

2.5. Cell Cycle Synchronization. Cell cycle synchronization was performed by double thymidine inhibition, as previously described [13]. Briefly, cells were incubated in growth medium to achieve approximately 40% confluency the following day. The medium was replaced with fresh medium containing 2 mM thymidine (Sigma-Aldrich) in PBS for 12 h, and the cells were then three times with PBS and incubated in fresh medium for a further 12 h. After this, the cells were thymidine-treated for a further 12h and then finally incubated in fresh medium containing chelidone or vehicle.

2.6. Western Blot Analysis. Whole-cell lysates were prepared using PRO-PREP[™] protein extraction solution (iNtRON Biotechnology, Seongnam, Korea) in the presence of a phosphatase inhibitor cocktail (Set V; Calbiochem, Darmstadt, Germany). The protein content of each cell lysate was quantified using the Bio-Rad Protein Assay system (Bio-Rad Laboratories), then lysates containing equivalent quantities of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF membranes (EMD Millipore Corporation, MA, USA). Membranes were blocked for 1 h at room temperature with 5% nonfat dry milk (BD Biosciences, NJ, USA) in TBS-T (TBS containing 0.05% Tween 20) and hybridized with the indicated primary antibodies overnight at 4°C. Membranes were then washed three times with TBS-T and incubated with peroxidase-conjugated goat anti-mouse or anti-rabbit secondary antibodies for 1 h at room temperature. Immunoreactive bands were visualized using Clarity[™] Western ECL Blotting Substrate (Bio-Rad Laboratories), followed by exposure to X-ray film (CP-BU new; AGFA, Mortsel, Belgium).

2.7. Immunofluorescence Assay. For immunofluorescence analysis, T98G cells were grown on a glass coverslip, fixed with 4% paraformaldehyde (BioShop, Burlington, ON, Canada) in PBS, washed with PBS, and permeabilized with 0.1% Triton X-100, before addition of the appropriate primary and secondary antibodies. Microscopy was performed with a confocal laser scanning microscope (FV1000; Olympus, Tokyo, Japan), and the images were captured and processed using FV10-ASW 3.1 Viewer software (Olympus).

3. Statistical Analysis

Statistical analysis was performed using the unpaired Student's *t*-test. Results were considered statistically significant

FIGURE 1: Chelidone induces apoptosis in human glioblastoma, T98G cell line. (a) The chemical structure of chelidone. (b) Human glioblastoma (T98G), lung cancer (A549), breast cancer (MCF7, MDA-MB-231), colon cancer (SW620) cell lines and noncancer (human embryonic kidney cell: HEK293, human umbilical vein endothelial cell: HUVEC, human fibroblast: CCD-25Sk) were treated with chelidone (1.0 μM) for 24 h, and a dimethylthiazolyl-carboxymethoxyphenyl-sulfophenyl-tetrazolium (MTS) assay was used to determine cell viability. (c) T98G cells were treated with the indicated concentration of chelidone for 24 h. The size of the sub G_{1/0} population of T98G cells, indicative of cell death, was determined by PI staining and flow cytometry analysis. (d) Whole T98G cell lysates were subjected to western blot analysis with the indicated antibodies. Cf; cleaved fragment. (e) Mitochondrial depolarization. Cells were stained with MitoTracker Red CMXRos and then analyzed using flow cytometry. Each experimental result represents the mean ± SEM of three independent experiments. * * *, $p < 0.001$, ** , $p < 0.01$, * , $p < 0.05$ by t -tests.

if $p < 0.05$. Error bars represent standard deviation derived from at least three independent experiments.

4. Results

4.1. Chelidone Induces Apoptosis in the T98G Human Glioblastoma Cell Line. To determine whether chelidone (Figure 1(a)) is cytotoxic in various human tumor cell lines, 1.0 μM chelidone was added to the indicated cell lines for 24 h, followed by MTS assay. Whereas chelidone had no or a little effect on survival in most of cells, it reduced the viability of T98G glioblastoma to about 60% (Figure 1(b)). To establish whether chelidone induces apoptosis in T98G

cell line, the sub-G_{1/0} population of the cells was analyzed on 24 h after treatment with chelidone. As shown in Figure 1(c), chelidone induced an increase in the sub-G_{1/0} population size in concentration-dependent manner. In particular, when 0.6 μM chelidone was used, the number of sub-G_{1/0} phase was significantly increased to about 10 times that of the control. To confirm that chelidone was inducing apoptosis, the expression of apoptosis-related proteins was analyzed by western blotting (Figure 1(d)). In particular, the level of Mcl-1 protein was significantly downregulated, and cleavage of caspase-3 and -9 was induced in chelidone-treated T98G cells. A reduction of in Mcl-1 protein could lead

FIGURE 2: *Chelidonine induces caspase-dependent and -independent apoptosis in T98G cells.* (a) Cells were pretreated with 50 μM Z-VAD-FMK for 1 h, followed by treatment with 0.6 μM chelidonine for 24 h. (b) Whole T98G cell lysates were subjected to western blot analysis with the indicated antibodies. The arrows indicate bands corresponding to cleaved caspase-9. Arrow: cleaved caspase-9. (c) T98G cells were synchronized by double thymidine inhibition, washed, and then incubated with 0.6 μM chelidonine for indicated periods of time after synchronization. They were then immunostained for AIF (red) and DNA (DAPI; blue). Images were captured using confocal laser scanning microscopy. Magnification, 600X. Scale bar, 10 μm .

to a reduction of mitochondrial outer membrane permeabilization (MOMP), which is a cause of apoptosis, and this was demonstrated in chelidonine-treated cells (Figure 1(e)).

4.2. Chelidonine Induces Apoptosis via Caspase-Dependent and -Independent Pathways. In order to confirm the induction of caspase-dependent apoptosis by chelidonine, T98G cells were treated with chelidonine in the presence or absence of the pan-caspase inhibitor Z-VAD, and then the size of the sub- $G_{1/0}$ population was determined using PI staining and flow cytometry (Figure 2(a)), and the statuses of caspase-3, caspase-9, and PARP were confirmed (Figure 2(b)). Although the pan-caspase inhibitor could inhibit cleavage of caspase-3, caspase-9, and PARP, apoptosis was only partially inhibited by the inhibitor. These results suggest that chelidonine might induce apoptosis through a caspase-independent pathway, as well as caspase-dependent pathway [14]. To investigate whether caspase-independent apoptosis was induced by

chelidonine, the translocation of AIF, a molecular marker, into the nucleus was analyzed after treatment with chelidonine for 24 hours (Figure 2(c)). This showed that AIF did translocate from the cytosol to the nucleus in chelidonine-treated cells, but remained in the cytosol of control cells. Taken together, these findings suggest that chelidonine might induce caspase-dependent apoptosis through caspase-3 and -9, but also caspase-independent apoptosis by inducing AIF translocation into the nucleus.

4.3. Chelidonine Induces $G_{2/M}$ Arrest in the T98G Cell Line. As a result of the effects described, chelidonine increased the number of cells in $G_{2/M}$ phase in the concentration-dependent manner (Figure 3(a)), in particular when 0.6 μM chelidonine was used (Figure 3(b)). To analyze its effects on the cell cycle more precisely, cells were synchronized at $G_{1/0}$ phase using double thymidine inhibition, before treatment with chelidonine. Vehicle or chelidonine was added after

FIGURE 3: Chelidonine induces $G_{2/M}$ arrest in T98G cells. T98G cells were seeded in six-well plates and incubated with the indicated concentration of chelidonine for 24 h (a). They were then stained with propidium iodide and analyzed with flow cytometry. (b) The numbers of cells in $G_{2/M}$ phase of cell cycle were analyzed using ModFit LTTM. (c) T98G cells were treated with 2 mM thymidine for 12 h, the thymidine was removed by washing with PBS (3 times), and fresh media was added to the culture plates for 12 h, after which they were retreated with 2 mM thymidine for 12 h. The $G_{1/0}$ arrested cells were then released by PBS washing and the addition of fresh medium containing 0.6 μM chelidonine or DMSO for the indicated periods of time. The cell cycle was analyzed at the indicated time points by PI staining and flow cytometry. The data show the percentages of cells in and $G_{2/M}$ phase (c) and sub- $G_{1/0}$ (d). Error bars represent the standard deviation. The data were analyzed using *t*-test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

synchronization of the cell cycle, and then the number of cells in each phase of the cell cycle was measured at each indicated time (Figure 3(c)). Control cells were mainly in $G_{2/M}$ phase after 8 h and the cell cycle was completed within about 12 h after synchronization. In contrast, cells treated with chelidonine were mainly in the $G_{2/M}$ phase, not only on 8 h but also on 12 h after synchronization. Twenty-four hours after chelidonine treatment, the number of cells in $G_{2/M}$

phase was lower and the size of the sub- $G_{1/0}$ population had significantly increased (Figures 3(c) and 3(d)). This suggests that apoptosis was induced in cells that do not progress from $G_{2/M}$ phase to $G_{1/0}$ phase.

4.4. The Prolonged $G_{2/M}$ Arrest Induced by Chelidonine Causes Apoptosis in T98G Cells. To investigate how chelidonine could induce $G_{2/M}$ arrest in T98G cells, spindle assembly, one

FIGURE 4: Chelidone-mediated $G_{2/M}$ arrest induces apoptosis in T98G cells. (a) Chelidone-mediated multipolar spindle assembly formation. T98G cells were synchronized at $G_{1/0}$ through double thymidine inhibition. After the synchronization, the cells were released and cultured in the presence or absence of 0.6 μ M chelidone for 12 or 18 h. Cells were immunostained for α -pericentrin (green), α -tubulin (red), and DNA (DAPI; blue). Images were captured using confocal laser scanning microscope. Magnification, 600 $\times$. (b) Whole-cell T98G lysates were subjected to western blot analysis with antibodies against cyclin B1, total or phosphorylated CDK1 (Tyr15 and Thr161), aurora A, total and phosphorylated PLK-1 (Thr210). Tubulin served as a loading control. (c) After the synchronization, cells were cultured in the presence or absence of 10 μ M RO-3306 and/or 0.6 μ M chelidone for 24 h. And then the whole-cell T98G lysates were subjected to western blot analysis with the indicated antibodies. (d and e) After the synchronization, cells were cultured in the presence or absence of 10 μ M RO-3306 and/or 0.6 μ M chelidone for 24 h. And then the mitochondrial potential (d) and the size of sub $G_{1/0}$ population (e) of T98G cells were determined by flow cytometry analysis. Each experimental result is shown as the mean and SEM of three independent experiments. The data was analyzed using *t*-test. * $p < 0.05$, ** $p < 0.01$.

of the features of the $G_{2/M}$ phase, was assessed using confocal microscopy (Figure 4(a)). After cell cycle synchronization, the cells were treated with chelidone for 12 or 18 h, and then spindle assembly and chromosome arrangement were assessed by staining for α -tubulin Ab, α -pericentrin Ab, and DAPI, respectively. While normal chromosome arrangement and bipolar spindle assembly were observed in vehicle-treated T98Gs, abnormal chromosome arrangement and multipolar spindle assembly were observed in chelidone-treated cells. This multipolar spindle assembly might be the cause of prolonged $G_{2/M}$ phase and lead some of mitotic cells to cell die. To determine the levels of $G_{2/M}$ marker proteins associated with chelidone-mediated $G_{2/M}$ arrest, western blotting was performed (Figure 4(b)). This showed that accumulation of cyclin B1, a reduction in inhibitory phosphorylation at Tyr15, and an increase in active phosphorylation at Thr161 of CDK1 were induced by chelidone. This implies that the cyclin B1/CDK1 complex is activated by chelidone and therefore that the $G_{2/M}$ phase is prolonged. However, the expressions of aurora kinase A (Aurora A), PLK1, and MPM-2 were also higher in chelidone-treated

cells. In the mitotic phase, active aurora A phosphorylates PLK1, and p-PLK1 activates Cdc25, which then dephosphorylates CDK1 at Tyr15 [15]. Therefore, the activities of Cdc25, CDK1, and cyclin B1/CDK1 complex were maintained longer in the chelidone-treated cells than in the control cells, providing a mechanism whereby chelidone might induce an accumulation of T98G cells in $G_{2/M}$ phase.

To establish whether higher activation of CDK1 induced the downregulation of Mcl-1, T98G cells were treated with chelidone in the presence or absence of RO-3306, CDK1 inhibitor, for 24 h after synchronization. The expression levels of Mcl-1, CDK1, and PARP were then measured by western blot analysis (Figure 4(c)), and MOMP and sub- $G_{1/0}$ population size were determined by PI staining and flow cytometry (Figures 4(d) and 4(e)). In fact, RO-3306 rescued the chelidone-mediated reduction in Mcl-1 expression and reduced the chelidone-induced apoptosis and cleavage of PARP. These data suggest that chelidone-mediated CDK1 is required for apoptosis through Mcl-1 degradation, as well as $G_{2/M}$ arrest.

5. Discussion

In this study, chelidonine showed cytotoxicity in T98G glioblastoma cells. Chelidonine induced apoptosis as well as $G_{2/M}$ arrest, which might be responsible for inducing apoptosis. There are three major causes of $G_{2/M}$ arrest, all of which involve the cyclin B1/CDK1 complex [16, 17]. $G_{2/M}$ arrest occurs when (a) the expression of cyclin B1 is reduced and therefore aberrant cyclin B1/CDK1 complexes are formed, (b) phosphorylation and dephosphorylation of CDK1 are not performed normally [18], or (c) the degradation of cyclin B1 does not occur in metaphase [19]. In this study, we present evidence that the accumulation of cyclin B1 and abnormal phosphorylation/dephosphorylation of CDK1 induce prolongation of $G_{2/M}$ (Figure 4(b)). Cyclin B1 is degraded by the E3 ubiquitin ligase, APC/C, in metaphase after activation of the cyclin B1/CDK1 complex [20]. Therefore, we propose that chelidonine induces $G_{2/M}$ arrest by interfering metaphase in T98G cells.

Interphase, prophase, prometaphase, metaphase, anaphase, telophase, and cytokinesis take place in that order during the $G_{2/M}$ phase. Immunofluorescence analysis showed multipolar spindle assembly in cells treated with chelidonine (Figure 4(a)). This event occurs when the spindle assembly checkpoint (SAC) of the $G_{2/M}$ phase is performed abnormally [21]. The SAC is turned on during prometaphase and normally turned off after metaphase is completed. At this stage, various proteins, including cyclin B1, are ubiquitinated by activated APC/C, which allows the cells to proceed with metaphase to anaphase transition [22]. In this study, it is likely that multipolar spindle assembly was the result of chelidonine-induced inactivation of APC/C, causing the accumulation of cyclin B1 and $G_{2/M}$ arrest. This multipolar spindle assembly influences a variety of events, mainly inducing apoptosis by mitotic slippage, mitotic catastrophe, or rarely by causing abnormal cell division [23].

For apoptosis to occur, the antiapoptotic protein, Mcl-1, is degraded, and the proapoptotic proteins, BAK and BAX, are activated, resulting in mitochondrial outer membrane permeabilization (MOMP). Damaged mitochondria induce apoptosis by releasing cytochrome C, endonuclease G, and AIF into the cytosol. Cytochrome C interacts with Apaf-1 to form apoptosome with procaspase-9, which activates caspase-3 and induces apoptosis through PARP cleavage (caspase-dependent apoptosis) [24]. However, endonuclease G and AIF can also translocate to the nucleus and cause DNA fragmentation, leading to caspase-independent apoptosis [25]. In this study, it was shown that cleavage of caspase-3, caspase-9, and PARP and translocation of AIF from mitochondria (cytosol) to the nucleus occur when T98G cells were treated with chelidonine. This suggests that chelidonine induces both caspase-dependent and -independent apoptosis. Mcl-1, which is located on the mitochondrial outer membrane, binds BAK and BAX and then inhibits their activities [26]. Mcl-1 is phosphorylated by various kinases such as GSK3 β , JNK, CDK1, and p38 [27] and then degraded by the ubiquitin proteasome system. In particular, phosphorylation of Mcl-1 by CDK1 might be a key bridge between $G_{2/M}$ arrest and apoptosis [28].

Taking these results together, chelidonine induces $G_{2/M}$ arrest through multipolar spindle assembly causing $G_{2/M}$ arrest in T98G cells, which likely induces both caspase-dependent and -independent apoptosis through Mcl-1 degradation. These findings suggest that chelidonine might represent a lead compound for anticancer chemotherapy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors' Contributions

Yeon-Kyeong Lee and Ki Won Lee contributed equally to this work.

Acknowledgments

This study was supported by the Next-Generation BioGreen21 (SSAC, PJ01318602), Rural Development Administration, Republic of Korea.

References

- [1] D. N. Louis, A. Perry, G. Reifenberger et al., "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary," *Acta Neuropathologica*, vol. 131, no. 6, pp. 803–820, 2016.
- [2] J. Zhou, K.-B. Atsina, B. T. Himes, G. W. Strohbehn, and W. M. Saltzman, "Novel delivery strategies for glioblastoma," *Cancer Journal*, vol. 18, no. 1, pp. 89–99, 2012.
- [3] J. Jakubowicz-Gil, E. Langner, D. Bądziul, I. Wertel, and W. Rzeski, "Apoptosis induction in human glioblastoma multipolar T98G cells upon temozolomide and quercetin treatment," *Tumor Biology*, vol. 34, no. 4, pp. 2367–2378, 2013.
- [4] A. M. P. Omuro, S. Faivre, and E. Raymond, "Lessons learned in the development of targeted therapy for malignant gliomas," *Molecular Cancer Therapeutics*, vol. 6, no. 7, pp. 1909–1919, 2007.
- [5] M. L. Colombo and E. Bosisio, "Pharmacological activities of *Chelidonium majus* L. (papaveraceae)," *Pharmacological Research*, vol. 33, no. 2, pp. 127–134, 1996.
- [6] M. Gilca, L. Gaman, E. Panait, I. Stoian, and V. Atanasiu, "Chelidonium majus - An integrative review: Traditional knowledge versus modern findings," *Forschende Komplementärmedizin*, vol. 17, no. 5, pp. 241–248, 2010.
- [7] Y.-C. Lee, S.-H. Kim, S.-S. Roh, H.-Y. Choi, and Y.-B. Seo, "Suppressive effects of *Chelidonium majus* methanol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice," *Journal of Ethnopharmacology*, vol. 112, no. 1, pp. 40–48, 2007.
- [8] L. Kokoska, Z. Polesny, V. Rada, A. Nepovim, and T. Vanek, "Screening of some Siberian medicinal plants for antimicrobial activity," *Journal of Ethnopharmacology*, vol. 82, no. 1, pp. 51–53, 2002.

- [9] J.-Y. Song, H.-O. Yang, S.-N. Pyo, I.-S. Jung, S.-Y. Yi, and Y.-S. Yun, "Immunomodulatory activity of protein-bound polysaccharide extracted from *Chelidonium majus*," *Archives of Pharmacal Research*, vol. 25, no. 2, pp. 158–164, 2002.
- [10] S. K. Nourine and M. Wink, "Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine," *World Journal of Gastroenterology*, vol. 15, no. 29, pp. 3603–3610, 2009.
- [11] U. Vahlensieck, R. Hahn, H. Winterhoff, H. G. Gumbinger, A. Nahrstedt, and F. H. Kemper, "The effect of *Chelidonium majus* herb extract on choleresis in the isolated perfused rat liver," *Planta Medica*, vol. 61, no. 3, pp. 267–271, 1995.
- [12] S. Mitra, M. Gole, K. Samajdar, R. K. Sur, and B. N. Chakraborty, "Antihepatotoxic activity of *Chelidonium majus*," *International Journal of Pharmacognosy*, vol. 30, no. 2, pp. 125–128, 1992.
- [13] J. V. Harper, "Synchronization of cell populations in G1/S and G2/M phases of the cell cycle," *Methods in Molecular Biology (Clifton, N.J.)*, vol. 296, pp. 157–166, 2005.
- [14] I. F. Sevrioukova, "Apoptosis-inducing factor: Structure, function, and redox regulation," *Antioxidants & Redox Signaling*, vol. 14, no. 12, pp. 2545–2579, 2011.
- [15] S. Zitouni, C. Nabais, S. C. Jana, A. Guerrero, and M. Bettencourt-Dias, "Polo-like kinases: Structural variations lead to multiple functions," *Nature Reviews Molecular Cell Biology*, vol. 15, no. 7, pp. 433–452, 2014.
- [16] M. Castedo, J. L. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. Kroemer, "Cell death by mitotic catastrophe: a molecular definition," *Oncogene*, vol. 23, no. 16, pp. 2825–2837, 2004.
- [17] R. S. DiPaola, "To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis," *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 2002, 3512–3519, 3311–3314.
- [18] J. A. Ubersax, E. L. Woodbury, P. N. Quang et al., "Targets of the cyclin-dependent kinase Cdk1," *Nature*, vol. 425, no. 6960, pp. 859–864, 2003.
- [19] Y. Nakayama and N. Yamaguchi, "Role of cyclin B1 levels in DNA damage and DNA damage-induced senescence," *International Review of Cell and Molecular Biology*, vol. 305, pp. 303–337, 2013.
- [20] E. Manchado, M. Eguren, and M. Malumbres, "The anaphase-promoting complex/cyclosome (APC/C): Cell-cycle-dependent and -independent functions," *Biochemical Society Transactions*, vol. 38, no. 1, pp. 65–71, 2010.
- [21] D. A. Brito, Z. Yang, and C. L. Rieder, "Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied," *The Journal of Cell Biology*, vol. 182, no. 4, pp. 623–629, 2008.
- [22] D. Izawa and J. Pines, "How APC/C-Cdc20 changes its substrate specificity in mitosis," *Nature Cell Biology*, vol. 13, no. 3, pp. 223–233, 2011.
- [23] K. E. Gascoigne and S. S. Taylor, "How do anti-mitotic drugs kill cancer cells?" *Journal of Cell Science*, vol. 122, no. 15, pp. 2579–2585, 2009.
- [24] C. Pop and G. S. Salvesen, "Human caspases: Activation, specificity, and regulation," *The Journal of Biological Chemistry*, vol. 284, no. 33, pp. 21777–21781, 2009.
- [25] S. P. Cregan, V. L. Dawson, and R. S. Slack, "Role of AIF in caspase-dependent and caspase-independent cell death," *Oncogene*, vol. 23, no. 16, pp. 2785–2796, 2004.
- [26] G. Dewson and R. M. Kluck, "Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis," *Journal of Cell Science*, vol. 122, no. 16, pp. 2801–2808, 2009.
- [27] C. H. Topham and S. S. Taylor, "Mitosis and apoptosis: how is the balance set?" *Current Opinion in Cell Biology*, vol. 25, no. 6, pp. 780–785, 2013.
- [28] R. Chu, D. T. Terrano, and T. C. Chambers, "Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration," *Biochemical Pharmacology*, vol. 83, no. 2, pp. 199–206, 2012.